Unicycive Therapeutics, Inc. (UNCY)
Develops medicines to treat kidney disease and related complications.
$4.94-0.04%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+17.6%
The outlook
UNCY is trading well below its moving averages and sits near the lower end of its 52-week range. Analyst sentiment leans bearish overall, though the average price target sits significantly above the current price. The stock remains thinly valued relative to consensus expectations, reflecting substantial disagreement between current market pricing and analyst views.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range24% of the way from its 52-week low to high
Price targetAvg target +681% vs current price
Analyst price target
~12-month · 10 analysts$38.59average target+681.2% vs now
Now $4.94
Low $13.00High $90.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$135.3M
52-wk high
$8.74
52-wk low
$3.71
50-day avg
$6.60
200-day avg
$6.36
Trailing P/E
—